DelveInsight

View All

Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika

Aurobindo Pharma Q2 net profit up 33.53% to Rs. 606 cr Aurobindo Pharma reported 33.53 per cent rise in consolidated net profit to Rs 605.64 crore for the quarter ending September mainly on account of robust formulation sales. The company had posted a net profit after tax, minority interest and share of profit of jo...

Find More

Estrogen Receptor Positive Breast Cancer: Market Outlook

Estrogen Receptor Positive Breast Cancer is the most common type of breast cancer diagnosed in the world. American Cancer Society has found that approximately two out of every three cases of breast cancer are hormone receptor positive. Approximately, 75% of cases of breast cancer are ER- Positive Breast Cancer and t...

Find More

Fresenius Kabi introduced Bivalirudin; Envigo Launches; Mylan’s MAA accepted; Pricing hit pharma

Fresenius Kabi introduced Bivalirudin for Injection Fresenius Kabi announced that it has introduced Bivalirudin for Injection in the United States, which is an anticoagulant, and a generic alternative to Angiomax. Fresenius Kabi’s Bivalirudin was approved by the U.S. Food and Drug Administration in October. The U.S....

Find More

Merck’s Antibody for Clostridium Difficile

Merck provided substantial evidence of safety and effectiveness for the approval of bezlotoxumab in June 2016 to the FDA, and the administration’s Antimicrobial Drugs Advisory Committee voted 10 to 5 with 1 abstention to recommend its approval. In October 2016, bezlotoxumab commercialized as Zinplava, got approved b...

Find More


DelveInsight’s Launch of Its New & Improved Report Store

DelveInsight is delighted to announce the launch of its report store. Our report store is collection of 3000+ analytical reports from the pharmaceutical as well as biotechnological industry. The store lets you browse through the vast collection of reports, gives you an overview of the different types of reports on o...

Find More

Cervical Cancer: Current Scenario

Cervical cancer is the second most common cause of death in women globally. Increased awareness and early diagnosis has reduced the death toll over the years; but still there is considerable risk that exists. According to the estimated of American Cancer Society, approximately 12,990 new cases of invasive cervical c...

Find More

PI3Kγ- a molecular switch that controls immune suppression

Macrophages play critical role in acute and chronic inflammation and cancer. In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T cells. Macrophage PI(3)Kinase γ controls a critical switch between immune stimulation and suppression during inflammation and cancer. ...

Find More

Graft vs Host Disease (GVHD): Treatment approaches and Trends

It is a well-known fact that where there is stem cell transplantation, there is Graft vs Host Disease (GVHD). The concept arose 2 decades ago and is not rare- it is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected, and attack t...

Find More

Roche’s drug; Cancer drugs risk; FDA norms; Takeda sets deal

Roche's drug candidate for Multiple Sclerosis touted to be better than Merck’s Rebif The much anticipated multiple sclerosis drug from Roche, ocrelizumab, has overtaken Merck’s Rebif according to the results of Phase III data, and has also shown great stats that could prove that it might have an edge in the hotly co...

Find More